via NewMediaWire – Shockwave Medical, Inc. (NASDAQ: SWAV) (“Shockwave”), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced...

Santa Clara, California--(Newsfile Corp. - April 11, 2023) - Shockwave Medical, Inc. (NASDAQ: SWAV) ("Shockwave"), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the completion of its previously announced acquisition of Neovasc Inc. ("Neovasc").

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Highlights ·       Generated revenue of $1.45 million in the fourth...

Vancouver, British Columbia--(Newsfile Corp. - March 6, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined below) have approved the previously-announced acquisition of all of the outstanding common shares of the Company (the "Shares") by Shockwave Medical, Inc. ("Shockwave") by way of a statutory plan of arrangement (the "Arrangement") at the special meeting of Shareholders held today (the "Meeting").

via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as defined...

via NewMediaWire – Neovasc, Inc. (“Neovasc” or “the Company”) (NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”) has awarded the Neovasc Reducer™ (“Reducer”), a CE-Marked medical device for the...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 1, 2023) - Neovasc, Inc. (NASDAQ : NVCN) (TSX : NVCN) ("Neovasc" or "the Company") today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023.

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding agreement (the "Arrangement Agreement") with Shockwave Medical, Inc. ("Shockwave"), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the "Common Shares") of the Company (the "Transaction").

Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc....

via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding...

TORONTO, Jan. 17, 2023 /CNW/ - Trading resumes in:

TORONTO, Jan. 17, 2023 /CNW/ - The following issues have been halted by IIROC:

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced an update on the COSIRA-II Clinical Trial ("Trial") status. COSIRA-II is the U.S. Investigational Device Exemption ("IDE") pivotal clinical trial the Company is executing for the Neovasc Reducer™ ("Reducer") towards an approval decision for the device in the United States. The Trial will randomize approximately 380 patients at up to 50 sites in North America. To date, 55 patients have been enrolled at 17 active sites. The Company has undertaken several initiatives to further accelerate enrollment in the Trial, including machine learning technology, expanding the field clinical team, and initiating enrollments in Canada. Neovasc aims to complete randomization in the first half of 2024.

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced an update on the COSIRA-II Clinical Trial (“Trial”) status. COSIRA-II is the U.S. Investigational Device Exemption (“IDE”) pivotal clinical trial the...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 18, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that European Heart Journal - Case Reports has published an article titled, "Implantation of the Coronary Sinus Reducer for Refractory Angina due to Coronary Microvascular Dysfunction in the Context of Apical Hypertrophic Cardiomyopathy - a Case Report." The article is authored by Dr. Kevin Cheng, et al, at the National Heart and Lung Institute Imperial College London, Royal Brompton Hospital, London.

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that European Heart Journal - Case Reports has published an article titled, “Implantation of the Coronary Sinus Reducer for Refractory Angina due to...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 10, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the third quarter ended September 30, 2022.

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Centers for Medicare and Medicaid Services ("CMS") has assigned the Neovasc Reducer™ ("Reducer") implant procedure a new outpatient reimbursement code payment status indicator, enabling U.S. hospitals to be reimbursed for the device and implant procedure.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Centers for Medicare and Medicaid Services (“CMS”) has assigned the Neovasc Reducer™ (“Reducer”) implant procedure a new outpatient...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm ET on November 10, 2022.

via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN) will report financial results for the quarter ended September 30, 2022 on Thursday, November 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief...

New Data Presented on the Neovasc Reducer(TM) in Patients With Microvascular Disease

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced positive clinical data at the Transcatheter Cardiovascular Therapeutics Conference (“TCT”) held September 16-19 in Boston. Prof. Shmuel Banai, MD, Neovasc...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 16, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24, 2022.

via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the LSI Europe 2022 Emerging MedTech Summit in Hertfordshire, United Kingdom on September 21-24,...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 15, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today commented on the Centers for Medicare and Medicaid Services ("CMS") development of new codes for the diagnosis and tracking of refractory angina. The new codes will be utilized in the current, 10th revision of the International Statistical Classification of Diseases and Related Health Problems Clinical Modification ("ICD-10-CM"). The latest update was published in the ICD-10-CM Tabular List of Diseases and Injuries 2023 Addenda and will be effective October 1, 2022.

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today commented on the Centers for Medicare and Medicaid Services (“CMS”) development of new codes for the diagnosis and tracking of refractory angina. The new codes...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 8, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference ("TCT"), hosted by the Cardiovascular Research Foundation ("CRF"), taking place in person at the Boston Convention & Exhibition Center, September 16-19, 2022. Members of the Neovasc team will be available at booth 647 in the exhibit hall.

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced its participation and presence at the Transcatheter Cardiovascular Therapeutics TCT 2022 conference (“TCT”), hosted by the Cardiovascular Research...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2022) - Neovasc, Inc. (Neovasc or the Company) (NASDAQ: NVCN) (TSX: NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022, in New York City. Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 1:30 pm ET on Tuesday, September 13, 2022.

via NewMediaWire – Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022, in New...

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Generated revenues of $818,000, a quarterly record and a...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 11, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2022.

via NewMediaWire – Neovasc Inc. (NASDAQ ,  TSX : NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 28, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on August 11, 2022.

via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device Exemption (“IDE”)...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - July 26, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the United States Food and Drug Administration ("FDA") has approved a protocol supplement to the COSIRA-II Investigational Device Exemption ("IDE") Trial. The approval expands the number of patients eligible for treatment in the trial and adds two previously planned imaging sub-studies designed to provide insights into the safety and mechanism of action of the Neovasc Reducer™ ("Reducer"). The timing of the approval is ahead of the Company's internal target and will allow for additional patients to be treated.

via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the company has expanded its direct sales operations in Europe to include the United Kingdom, effective July 1, 2022. The company has hired its...

Expansion Driven by NICE Guidelines and Enhanced Reimbursement for the Neovasc Reducer(TM)

via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference to be held June 15-16, 2022....

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 8, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference to be held June 15-16, 2022. Neovasc's Chief Operating Officer, Bill Little, will be presenting at 1:45 pm ET on Wednesday, June 15.

via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. Fred Colen, Neovasc’s...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 23, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced that its management team will be participating in the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. Fred Colen, Neovasc's President and Chief Executive Officer, will be presenting at 11:00 am ET on Wednesday, May 25.

via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has received written notification from the Nasdaq Stock Market LLC (the “Nasdaq”) informing the Company that it has regained compliance with...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 16, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification from the Nasdaq Stock Market LLC (the "Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the quarter ended March 31, 2022. Recent Highlights ·       Achieved Q1 revenue of approximately $611,000, an increase of 35%...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 12, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the quarter ended March 31, 2022.

via NewMediaWire -- Neovasc Inc. (NASDAQ ,  TSX : NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 29, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on May 12, 2022.

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the European Heart Journal has published an article entitled, “Impact of the Coronary Sinus Reducer on Absolute Blood Flow and Microvascular...

Report demonstrates objective improvements in patients suffering from microvascular dysfunction

via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter...

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that the Company has filed articles of amendment, effective today, to effect the previously announced share consolidation (reverse stock split) (the "Consolidation") of its issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidation Common Share for every twenty-five (25) pre-Consolidation Common Shares. The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 68,228,061 Common Shares to approximately 2,729,107 Common Shares. The Common Shares are expected to commence trading on the Toronto Stock Exchange (the "TSX") and on the Nasdaq Capital Market (the "Nasdaq") on a post-Consolidation basis on or about the opening of trading on April 29, 2022.

via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022. Fred Colen,...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX : NVCN) (Neovasc or the Company) today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022. Fred Colen, Neovasc's Chief Executive Officer, will be presenting at 4:00 pm ET on Monday, May 2.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April 12, 2022 in Vancouver,...

New York, New York--(Newsfile Corp. - April 13, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) "Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April 12, 2022 in Vancouver, B.C. (the "Meeting").

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter...

Vancouver, British Columbia--(Newsfile Corp. - March 24, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that, pursuant to a Restated Securities Purchase Agreement with Strul Medical Group LLC ("SMG"), on a private placement basis (the "Private Placement"), it has issued an amended and restated convertible note (the "2022 Restated Note").

via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021. Highlights Achieved record revenue in Q4 of $759,000, an increase of 48%...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 10, 2022) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2021.

via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief...

Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter and full year ended December 31, 2021 on Thursday, March 10, 2022. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on March 10, 2022.

via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 8, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the German Institute for the Hospital Remuneration System ("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation yet again for 2022. Additionally, the Company announced the 500th patient has been treated in Germany.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 4, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc ReducerTM ("Reducer").

via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc  Reducer™ (“Reducer”). The two analyses, authored by Americo...

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation,...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 2, 2022) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), today announced the complete dismissal of the consolidated amended complaint in the shareholder class action case captioned In re Neovasc Inc. Securities Litigation, Case No. 7:20-cv-09313, filed in the United States District Court for the Southern District of New York. The consolidated amended complaint was dismissed in its entirety with prejudice and without leave to amend.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 20, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (Neovasc or the Company) today announced the publication of an article entitled, "The Effectiveness of CS Reducer for the Treatment of Refractory Angina - a Meta-Analysis" in the Canadian Journal of Cardiology.

via NewMediaWire -- Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “The Effectiveness of CS Reducer for the Treatment of Refractory Angina – a Meta-Analysis” in the Canadian...

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer™...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 18, 2022) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of a case series in the journal Cardiovascular Revascularization Medicine describing successful uses of the Neovasc Reducer™ ("Reducer") under a compassionate use protocol in the United States. The patients were treated under the care of Ryan Gindi, M.D., and the procedures were performed by Gerald Koenig, M.D., Ph.D, both from the Division of Cardiology, Henry Ford Hospital, Detroit. Following the commencement of the COSIRA-II Trial in the United States, qualifying patients are now eligible to be treated in a clinical trial for the device.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 6, 2022) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022. A recorded presentation by Fred Colen, Neovasc's Chief Executive Officer, will be available on the conference website starting at 7:00 am EST on Monday, January 10. The recording will be archived for 90 days.

via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 2022 H.C. Wainwright BIOCONNECT Virtual Conference to be held January 10-13, 2022.  A recorded...

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced enrollment of the first patient in the COSIRA-II clinical trial. COSIRA-II (COronary SInus Reducer for the Treatment of Refractory Angina) is a...

COSIRA-II Trial Designed to Study the Neovasc Reducer(TM) for Patients with Refractory Angina

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that its management team will be participating in the Sidoti December Virtual Microcap Conference to be held December 8-9, 2021.  Fred Colen,...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 1, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the Sidoti December Virtual Microcap Conference to be held December 8-9, 2021. Fred Colen, President and Chief Executive Officer, will give a presentation on Wednesday, December 8 at 3:15 pm EST. A link to the live webcast of the presentation will be available in the Investor Relations section of the Neovasc website at https://www.neovasc.com/investors/. The recording will be archived for 90 days.

First therapy to receive newly established French reimbursement designation

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer™ (“Reducer”) system has been granted Prise en Charge Transitoire (“PECT”) reimbursement in France by the national health...

via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that in accordance with Nasdaq Listing Rule...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), Nasdaq has granted an additional 180 calendar day period within which to evidence compliance with the $1.00 bid price requirement following the expiration of the current compliance period on November 22, 2021.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the United Kingdom’s Interventional Procedures Programme at the National Institute for Health and Care Excellence (“NICE”) has issued guidance...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 24, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the United Kingdom's Interventional Procedures Programme at the National Institute for Health and Care Excellence ("NICE") has issued guidance supporting the implantation of the Neovasc Reducer™ ("Reducer") in appropriate patients suffering from refractory angina, a painful and debilitating condition that causes chest pain when other treatment options have failed or are not possible.

via NewMediaWire --Neovasc, Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today reported financial results for the third quarter ended September 30, 2021.  Third Quarter Highlights Strong progress against all three...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 9, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the third quarter ended September 30, 2021.

via NewMediaWire – Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial...

Vancouver, British Columbia--(Newsfile Corp. - November 1, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the quarter ended September 30, 2021 on Tuesday, November 9, 2021. Neovasc's President and Chief Executive Officer Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the company's results at 4:30 pm EDT on November 9, 2021.

Publication Highlights Device Success in Chronic Total Occlusions of the Right Coronary Artery

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer™ (“Reducer”) is featured in an article published in the latest issue of the Polish Heart Journal. Entitled “Efficacy of...

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 28, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of an article entitled, "Coronary sinus narrowing for the treatment of refractory angina: a multicentre prospective open-label clinical study (the REDUCER-I study)" in the September 2021 issue of the journal EuroIntervention.

via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 2021 Benzinga Healthcare Small Cap Conference to be held September 29-30, 2021.  Bill Little,...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 23, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the 2021 Benzinga Healthcare Small Cap Conference to be held September 29-30, 2021. Bill Little, Neovasc's Chief Operating Officer, will give a presentation on Wednesday, September 29 at 4:00 pm EDT. A link to the live webcast of the presentation will be available in the Investor Relations section of the Neovasc website at https://www.neovasc.com/investors/. The recording will be archived for 90 days.

Company on Schedule to Commence Trial Late This Year

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received FDA approval for the Investigational Device Exemption (“IDE”) regarding the COSIRA-II IDE Clinical Trial.  Following multiple...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 30, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September 13-15, 2021. A pre-recorded company presentation will be available beginning at 7:00 am EDT on September 13 through the conference website and the Investor Relations section of the Neovasc website at https://www.neovasc.com/investors/. The recording will be archived for 90 days.

via NewMediaWire – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ,TSX: NVCN) today announced that its management team will be participating in the 23rd Annual H.C. Wainwright Global Investment Conference to be held September 13-15, 2021. A...

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA)....

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 17, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has filed a supplement to the COSIRA-II Investigational Device Exemption (IDE) Study with the U.S. Food and Drug Administration (FDA). Following multiple productive discussions with FDA over the past several months, the protocol for the previously approved COSIRA-II study has been supplemented in consideration of additional experience and key questions arising from the October 2020 Circulatory Systems Devices Panel Meeting regarding the Neovasc Reducer™ ("Reducer").

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the second quarter ended June 30, 2021. Second Quarter Highlights Generated...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 10, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today reported financial results for the second quarter ended June 30, 2021.

via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021.  Neovasc’s President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief...

Vancouver, British Columbia--(Newsfile Corp. - July 27, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), will report financial results for the second quarter ended June 30, 2021 on Tuesday, August 10 2021. Neovasc's President and Chief Executive Officer, Fred Colen, and Chris Clark, Chief Financial Officer, will host a conference call to review the Company's results at 4:30 pm EDT.

Neovasc Team Grows with Addition of Industry Veterans Lisa Becker as VP, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as VP of Clinical Affairs

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has appointed Lisa Becker as Vice President, Regulatory Affairs, Global Angina Therapies and Sarah Gallagher as Vice President, Clinical...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 18, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced the publication of an article entitled, "Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE Study" in the International Journal of Cardiology.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE...

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the publication of an article entitled, “Safety and Efficacy of Coronary Sinus Narrowing in Chronic Refractory Angina: Insights from the RESOURCE...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - June 10, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its cash runway well into 2024, focusing investments on near term value drivers, and more deeply reviewing the Company's core business activities.

TORONTO, June 10, 2021 /CNW/ - Trading resumes in:

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Company has implemented a series of strategic initiatives focused on enhancing current shareholder value, minimizing dilution, extending its...

TORONTO, June 10, 2021 /CNW/ - The following issues have been halted by IIROC:

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Neovasc Reducer® (“Reducer”) system has been granted national reimbursement in England as a result of being included in the High-Cost Tariff...

NHS England Provides National Coverage

Vancouver, British Columbia--(Newsfile Corp. - June 3, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 3, 2021 in Vancouver, B.C. (the "Meeting").

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on June 3, 2021 in Vancouver, B.C. (the...

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 25, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from April 12, 2021 to May 21, 2021, the Company no longer meets the minimum bid price requirement.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) reported today that the Higher Regional Court in Munich, Germany has upheld the first instance judgment of the Regional Court Munich of June 16, 2017, in which the...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 20, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") reported today that the Higher Regional Court in Munich, Germany has upheld the first instance judgment of the Regional Court Munich of June 16, 2017, in which the court had found that Edwards Lifesciences LLC ("Edwards") had contributed in part to the invention of the Tiara™ and awarded to Edwards co-entitlement rights to the disputed Tiara™ European patent application. There are no monetary awards associated with these matters and no damages award was recognized.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 13, 2021) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer™ ("Reducer"), highlighting its easy integration into current cardiovascular and microvascular disease treatments. The symposium titled, "Latest clinical evidence and practical aspects to start Reducer therapy in your center," will be presented at the 2021 EuroPCR, taking place digitally from May 18-20, 2021. EuroPCR is a leading opportunity for cardiologists to exchange ideas and latest best practices.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer™ (“Reducer”), highlighting its easy integration into...

via NewMediaWire ‒ Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina (“COSIMA”) trial. The...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 10, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina ("COSIMA") trial. The enrollment occurred at University Hospital, Mainz, Germany. The patient is an 82-year-old woman who suffers from severe Canadian Cardiovascular Society ("CCS") Class IV angina on a daily basis despite optimal medical treatment. The study is being led by Prof. Tommaso Gori, M.D., Ph.D., University Medical Center, Mainz, Germany.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - May 6, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today reported financial results for the first quarter ended March 31, 2021.

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the first quarter ended March 31, 2021. First Quarter Highlights Generated revenue of $451,794 in the quarter as Neovasc...

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced progress towards its value creation strategy of expanding global reimbursement for the Neovasc Reducer™ (“Reducer”). Expanding reimbursement for the...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 28, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced progress towards its value creation strategy of expanding global reimbursement for the Neovasc Reducer™ ("Reducer").

via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN) will report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021.  Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 27, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) will report financial results for the first quarter ended March 31, 2021 on Thursday, May 6, 2021. Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company's results at 4:30 pm EST.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 19, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the journal EuroIntervention has published an article entitled, "Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina."

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the journal EuroIntervention has published an article entitled, “Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - April 16, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today announced that the Tiara Transapical system ("Tiara TA") will be unable to receive a European CE mark under the current Medical Device Directive regulations ("MDD") ending on May 26, 2021. The Company is collaborating with its European Notified Body (the "Notified Body") on potential next steps.

via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced that the Tiara Transapical system (“Tiara TA”) will be unable to receive a European CE mark under the current Medical Device Directive regulations...

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020. Fourth Quarter Highlights...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 11, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today reported financial results for the fourth quarter and fiscal year ended December 31, 2020.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 4, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) will report results for the fourth quarter and fiscal year ended December 31, 2020 after the market close on Thursday, March 11, 2021. Neovasc President and Chief Executive Officer Fred Colen and Chief Financial Officer Chris Clark will host a conference call to review the Company's results at 4:30 pm EST.

via NewMediaWire -- Neovasc, Inc. (NASDAQ, TSX: NVCN) will report results for the fourth quarter and fiscal year ended December 31, 2020 after the market close on Thursday, March 11, 2021.  Neovasc President and Chief Executive Officer Fred Colen...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 3, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the 2021 H.C. Wainwright Global Life Sciences Conference that is scheduled to take place March 9-10, 2021. A recorded presentation by Bill Little, Neovasc's Chief Operating Officer, will be available on the Conference website starting at 7:00 am EST on March 9. Company management will also be scheduling one-on-one meetings with investors; meetings may be requested through H.C. Wainwright.

via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the 2021 H.C. Wainwright Global Life Sciences Conference that is scheduled to take place March 9-10, 2021.  A recorded...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - March 2, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the journal Clinical Cardiology has published an article entitled, "Long-term outcomes of patients undergoing coronary sinus reducer implantation - A multicenter study."

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the journal Clinical Cardiology has published an article entitled, “Long-term outcomes of patients undergoing coronary sinus reducer...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 24, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum market value requirement set forth in the rules for continued listing on the Nasdaq Capital Market (the "Listing Rules").

via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), has received written notification (the "Nasdaq Notice") from the Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the...

Vancouver, British Columbia--(Newsfile Corp. - February 17, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference that is scheduled to take place from February 24 to 26, 2021. Fred Colen, Neovasc's President and Chief Executive Officer, will present on Friday, February 26, 2021 at 1:00 pm EST.

via NewMediaWire -- Neovasc Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference that is scheduled to take place from February 24 to 26, 2021. Fred...

Vancouver, British Columbia--(Newsfile Corp. - February 12, 2021) - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN) announced today that it has closed its previously announced sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 per common share in a registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules for aggregate gross proceeds to the Company of approximately US$72 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company.

via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq: NVCN / TSX: NVCN) announced today that it has closed its previously announced sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 per common share in...

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 36,000,000 common shares at a purchase price of US$2.00 per common share in a registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules for aggregate gross proceeds to the Company of approximately US$72 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company. The Offering is expected to close on or about February 12, 2021, subject to customary closing conditions.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 9, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification from the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) pursuant to Nasdaq Listing Rule 5810 for continued listing on the Nasdaq.

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has received written notification from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 5, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the Journal of the American Heart Association has published an article entitled, "Angina Severity, Mortality, and Healthcare Utilization Among Veterans with Stable Angina". The prestigious journal is the official publication of the American Heart Association, and the article offers important insights into the burden of angina on both patients and healthcare systems.

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the Journal of the American Heart Association has published an article entitled, “Angina Severity, Mortality, and Healthcare Utilization Among...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - February 2, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the German Institute for the Hospital Remuneration System("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation once again for 2021.

via NewMediaWire -- Neovasc,  Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the German Institute for the Hospital Remuneration System("InEK") has awarded the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device for...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 29, 2021) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT®) Category III Code for transcatheter implantation of a coronary sinus reduction device. The code is effective July 1, 2021.

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that the American Medical Association (AMA) has issued a new Current Procedural Terminology (CPT®) Category III Code for transcatheter implantation...

Vancouver, Bristish Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 19, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that the Neovasc Reducer™ ("Reducer") was prominently featured in three peer reviewed European Journals.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today the Neovasc Reducer™ (“Reducer”) was prominently featured in three peer reviewed European Journals.   “Management of refractory angina: an...

Vancouver, British Columbia--(Newsfile Corp. - January 15, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received a "not-approvable" letter from U.S. Food & Drug Administration (FDA) regarding its PMA submission for the Neovasc Reducer™ (Reducer).

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received a “not-approvable” letter from U.S. Food & Drug Administration (FDA) regarding its PMA submission for the Neovasc Reducer™...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 4, 2021) -  Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) today announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which takes place January 11-14, 2021. Neovasc President and Chief Executive Officer Fred Colen, Chief Operating Officer Bill Little, and Chief Financial Officer Chris Clark will be available for one-on-one investor meetings during the event; meetings may be requested through H.C. Wainwright. Additionally, a webcast of Neovasc's recorded company presentation will be available on demand via the H.C. Wainwright conference site beginning at 6:00 am ET on January 11, and on the Neovasc website at https://www.neovasc.com/presos/.

via NewMediaWire -- Neovasc Inc. (Nasdaq, TSX: NVCN), today announced its participation in the H.C. Wainwright BioConnect 2021 Virtual Conference, which takes place January 11-14, 2021.  Neovasc President and Chief Executive Officer Fred Colen,...

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that EuroIntervention, the official journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI), has published...

REDUCER I Study Shows Improvement in Chest Pain Symptoms

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 15, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has completed the first three Neovasc Reducer™ ("Reducer") implants in France. The implants are an important step for Neovasc as the Company continues to expand access for Reducer therapy to patients suffering from refractory angina.

via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has completed the first three Neovasc Reducer™ (“Reducer”) implants in France. The implants are an important step for Neovasc as the Company...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 14, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's common shares for the 30 consecutive business days from October 30, 2020 to December 11, 2020, the Company no longer meets the minimum bid price requirement.

via NewMediaWire -- Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 10, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") , announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US$35 million and Listing Rule 5810(c)(3)(C) provides that a failure to meet the market value requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the market value of the Company for the 30 consecutive business days from October 28, 2020 to December 9, 2020, the Company no longer meets the minimum market value requirement.

via NewMediaWire -- Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX:NVCN), announced today that it has received written notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 10, 2020) -  Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules of an aggregate of 6,230,803 common shares at a price of US$0.9801 per common share. Aggregate gross proceeds to the Company were approximately US$6.1 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company.

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 8, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 6,230,803 common shares at a purchase price of US$0.9801 per common share in a registered direct offering (the "Offering") priced at-the-market under the Nasdaq Capital Market (the "Nasdaq") rules. Aggregate gross proceeds to the Company are approximately US$6.1 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company. The Offering is expected to close on or about December 10, 2020, subject to satisfaction of customary closing conditions.

via NewMediaWire -- Neovasc, Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 6,230,803...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - December 1, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today announced their participation in Noble Capital Markets' Virtual Road Show Series, presented by Channelchek, scheduled for December 8, 2020.

via NewMediaWire -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced their participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, scheduled for December 8, 2020. The virtual...

Vancouver, British Columbia--(Newsfile Corp. - November 16, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN), today announced that company management will be participating in the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020. Fred Colen, Neovasc's President and Chief Executive Officer, will deliver a presentation at 11:00 am EST. Mr. Colen will also be joined by Chief Financial Officer Chris Clark, and Chief Operating Officer Bill Little, for investor meetings throughout the day.

via NewMediaWire – Neovasc, Inc. (NASDAQ, TSX: NVCN), today announced that company management will be participating in the Canaccord Genuity 2020 Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020.  Fred Colen, Neovasc’s President...

via NewMediaWire -- Neovasc, Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - November 5, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the third quarter ended September 30, 2020.

via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that the United States Food and Drug Administration’s (FDA’s) Circulatory System Devices Advisory Panel voted 14 to 4 “in favor” that the Neovasc...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 28, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that the United States Food and Drug Administration's (FDA's) Circulatory System Devices Advisory Panel voted 14 to 4 "in favor" that the Neovasc Reducer™ is safe when used as intended, and voted 1 to 17 "against" on the issue of a reasonable assurance of effectiveness. The third vote was 13 to 3 "against" (2 abstained) on whether the relative benefits outweighed the relative risks.

via NewMediaWire -- Neovasc, Inc. (NASDAQ, TSX: NVCN) today announced that it will report financial results for the quarter ended September 30, 2020 after the market close on November 5, 2020.  Neovasc President and Chief Executive Officer Fred...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 22, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) today announced that it will report financial results for the quarter ended September 30, 2020 after the market close on November 5, 2020. Neovasc President and Chief Executive Officer Fred Colen, and Chief Financial Officer Chris Clark will host a conference call to review the company's results at 4:30 PM Eastern Time.

via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium entitled “Unmet Need in Treating Patients With Refractory Angina” at the 2020 TCT Connect Online Conference, taking...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - October 13, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") today announced that it will sponsor a symposium entitled "Unmet Need in Treating Patients With Refractory Angina" at the 2020 TCT Connect Online Conference, taking place October 14-18, 2020.

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - September 8, 2020) -  Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today announced that its management team will be participating in the 22nd Annual H.C. Wainwright Global Investment Conference on September 14-16, 2020. Fred Colen, Neovasc's President and CEO, will present on September 15 at 3:30 pm EDT.

via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of...

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on September 3, 2020 in Vancouver, B.C. (the "Meeting").

via NEWMEDIAWIRE -- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on September 3, 2020 in Vancouver, B.C. (the...

via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that Strul Medical Group LLC (“SMG”) exercised 501,000 of the remaining 1,149,910 common share purchase warrants (the “May Warrants”) issued pursuant...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 17, 2020) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company") announced today that Strul Medical Group LLC ("SMG") exercised 501,000 of the remaining 1,149,910 common share purchase warrants (the "May Warrants") issued pursuant to a Securities Purchase Agreement dated May 26, 2020 at an exercise price of US$2.634 per May Warrant for aggregate exercise proceeds to the Company of US$1,319,634.00 (the "Exercise Proceeds").

via NEWMEDIAWIRE  -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today provided a corporate update on progress towards its value creation strategies.  Fred Colen, Chief Executive Officer of Neovasc, commented, “We are pleased...

Vancouver, British Columbia and Minneapolis, Minnesota--(Newsfile Corp. - August 13, 2020) - Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), today provided a corporate update on progress towards its value creation strategies.

Vancouver, British Columbia--(Newsfile Corp. - August 12, 2020) -  Neovasc Inc. (NASDAQ: NVCN)  (TSX: NVCN) ("Neovasc" or the "Company") announced today that it has closed its previously announced registered direct offering (the "Offering") priced at-the-market under the Nasdaq rules of an aggregate of 4,532,772 common shares at a purchase price of US$2.77575 per common share for aggregate gross proceeds to the Company of approximately US$12.6 million, before deducting placement agent's fees and estimated expenses of the Offering payable by the Company.